Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

February 26, 2026 - 20:17

CRANBURY, N.J., February 26, 2026—Rocket Pharmaceuticals, a late-stage biotechnology firm, has released its financial and operational results for the fourth quarter and full year ending December 31, 2025. The company highlighted significant progress across its pipeline of genetic therapies for rare disorders.

Operational achievements throughout the year included key regulatory advancements for its lead clinical programs. The company reported positive momentum in its trials for Fanconi Anemia and Leukocyte Adhesion Deficiency-I, noting continued engagement with health authorities. These milestones underscore the company's focus on advancing potential treatments for conditions with limited existing options.

Financially, Rocket Pharmaceuticals ended the year with a strong cash position, which it states is sufficient to fund planned operations into the latter part of 2027. This runway is intended to support the ongoing development of its core programs through important clinical and regulatory stages. The company's research and development expenses reflect its continued investment in bringing these novel genetic therapies forward.

Leadership expressed confidence that the past year's progress has solidified the company's trajectory. The focus remains on executing clinical and regulatory strategies to deliver therapies to patients awaiting new options. The reported financial resources are deemed adequate to reach several anticipated value-driving milestones over the coming years.